Molecular Financial Statements From 2010 to 2025
| MLLCF Stock | USD 4.22 0.00 0.00% |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers, such as , as well as many indicators such as . Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular |
Molecular Partners AG Company Return On Asset Analysis
Molecular Partners' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Molecular Partners Return On Asset | 0.32 |
Most of Molecular Partners' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Molecular Partners AG has a Return On Asset of 0.3163. This is 103.61% lower than that of the Healthcare sector and 101.34% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably lower than that of the firm.
Molecular Partners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Partners's current stock value. Our valuation model uses many indicators to compare Molecular Partners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Partners competition to find correlations between indicators driving Molecular Partners's intrinsic value. More Info.Molecular Partners AG is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.51 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Molecular Partners AG is roughly 1.97 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Molecular Partners' earnings, one of the primary drivers of an investment's value.About Molecular Partners Financial Statements
Molecular Partners stakeholders use historical fundamental indicators, such as Molecular Partners' revenue or net income, to determine how well the company is positioned to perform in the future. Although Molecular Partners investors may analyze each financial statement separately, they are all interrelated. For example, changes in Molecular Partners' assets and liabilities are reflected in the revenues and expenses on Molecular Partners' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Molecular Partners AG. Please read more on our technical analysis and fundamental analysis pages.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 163 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Molecular Pink Sheet
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out the analysis of Molecular Partners Correlation against competitors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.